Mirum Pharmaceuticals Deal History & Licensing Activity
Mirum Pharmaceuticals is a biotech headquartered in US. Over the past three years, Mirum Pharmaceuticals has been involved in 3 licensing and acquisition transactions, with a primary focus on Small Molecules (2 deals). The company currently has 21 active clinical trials, primarily in Infectious.
Deals (12mo)
2
Active Trials
21
Top Modality
Small Molecules
Focus Area
Infectious
Mirum Pharmaceuticals Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Mirum Pharmaceuticals in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| zilurgisertib | Incyte | Small Molecules | Phase 3 | license | Apr 1, 2026 |
| brelovitug (BJT-778) | Bluejay Therapeutics | Other | Phase 3 | acquisition | Dec 8, 2025 |
Mirum Pharmaceuticals Pipeline Focus
Therapeutic areas and modalities where Mirum Pharmaceuticals is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Mirum Pharmaceuticals Strategic Signals
Key indicators of Mirum Pharmaceuticals's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Mirum Pharmaceuticals Clinical Pipeline
Mirum Pharmaceuticals has 21 active clinical trials across 5 development phases.
6
Unknown
1
Phase 4
6
Phase 2
4
Phase 2/3
4
Phase 3
See How Your Asset Matches Mirum Pharmaceuticals's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Infectious assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Dermatology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for dermatology
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Mirum Pharmaceuticals Licensing & Deal Activity
Mirum Pharmaceuticals is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Mirum Pharmaceuticals ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Mirum Pharmaceuticals include Infectious (6 deals and trials), Dermatology (5 deals and trials), Rare Disease (3 deals and trials), and Gastroenterology (3 deals and trials). In terms of modality, Mirum Pharmaceuticals has shown particular interest in small molecules, other, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Mirum Pharmaceuticals and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Mirum Pharmaceuticals's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.